[1] |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021,71:7-33.
|
[2] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71:209-249.
|
[3] |
薛剑超, 王亚东, 李博文, 等. DNA甲基化在肺癌发生及预后中作用的研究进展[J]. 基础医学与临床, 2023,43:514-518.
|
[4] |
任孟先, 梁伟, 刘艳. 塞来昔布联合IMRT对老年中晚期非小细胞肺癌患者免疫功能和血清肿瘤标志物的影响[J]. 基础医学与临床, 2021,41:890-894.
|
[5] |
Signorile A, Sgaramella G, Bellomo F, et al. Prohibitins: a critical role in mitochondrial functions and implication in diseases[J]. Cells, 2019,8:278-286.
|
[6] |
Wu B, Chang N, Xi H, et al. PHB2 promotes tumorigenesis via RACK1 in non-small cell lung cancer[J]. Theranostics, 2021,11:3150-3166.
|
[7] |
Kasashima K, Ohta E, Kagawa Y, et al. Mitochondrial functions and estrogen receptor-dependent nuclear translocation of pleiotropic human prohibitin 2[J]. J Biol Chem, 2006,281:36401-36410.
|
[8] |
Cai XW, Yu WW, Yu W, et al. Tissue-based quantita-tive proteomics to screen and identify the potential biomarkers for early recurrence/metastasis of esophageal squamous cell carcinoma[J]. Cancer Med, 2018,7:2504-2517.
|
[9] |
Cheng J, Gao F, Chen X, et al. Prohibitin-2 promotes hepatocellular carcinoma malignancy progression in hypoxia based on a label-free quantitative proteomics strategy[J]. Mol Carcinog, 2014,53:820-832.
|
[10] |
Cao Y, Liang H, Zhang F, et al. Prohibitin overexpres-sion predicts poor prognosis and promotes cell proliferation and invasion through ERK pathway activation in gallbl-adder cancer[J]. J Exp Clin Cancer Res, 2016,35:68-78.
|
[11] |
Yapa N, Lisnyak V, Reljic B, et al. Mitochondrial dynamics in health and disease[J]. FEBS Lett, 2021,595:1184-1204.
|
[12] |
Srinivasan S, Guha M, Kashina A, et al. Mitochondrial dysfunction and mitochondrial dynamics-the cancer connection[J]. Biochim Biophys Acta Bioenerg, 2017,1858:602-614.
|
[13] |
Willems PH, Rossignol R, Dieteren CE, et al. Redox homeostasis and mitochondrial dynamics[J]. Cell Metab, 2015,22:207-218.
|
[14] |
Serasinghe MN, Chipuk JE. Mitochondrial fission in human diseases[J]. Handb Exp Pharmacol, 2017,240:159-188.
|
[15] |
Wu B, Xiong J, Zhou Y, et al. Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission[J]. Arch Biochem Biophys, 2020,692:108539-108543.
|